Research Interests:

Prostate cancer is a hormone-dependent malignancy, tumor progression depends on androgen receptor (AR) presence and function, and the endogenous ligands for AR, testosterone (T) and 5α-dihydrotestosterone (DHT), are the main androgens fueling the growth of malignant cells. Currently, direct inhibitions of AR and androgen synthesis are the main strategies, which makes antiandrogens, such as enzalutamide (ENZ) and abiraterone, are widely used in the prostate cancer therapy. Unfortunately, antiandrogen resistance happens to almost all the advanced prostate cancer patients and eventuates into disease lethality, hence, developing new treatment strategies to circumvent resistance is critical and urgent.